Literature DB >> 16210408

Differentiation of human embryonic stem cells after transplantation in immune-deficient mice.

Stefan A Przyborski1.   

Abstract

Our current knowledge of how human tissues grow and develop is limited. We need to increase our understanding of tissue formation if we are to fully realize the potential of stem cells as a source of material for research into health and disease and possible therapeutic applications. Transplanted pluripotent human embryonic stem cells (hESCs) provide a potential system to model and investigate cell differentiation in humans. hESCs transplanted into immune-deficient mice form complex teratomas consisting of a range of differentiated somatic tissues, some of which appear highly organized and resemble structures normally identified in the embryo and adult. Analysis of such tumors may provide a unique opportunity to study organogenesis and lead to novel approaches in bioengineering and the growth of functioning structures composed of a range of alternative cell types. However, little has been done to characterize the developmental potential of hESCs after transplantation. This concise review presents evidence for the ability of hESCs to differentiate in vivo and highlights some of the prominent questions that need to be addressed if transplantation is to be used as a research tool to study hESC differentiation.

Entities:  

Mesh:

Year:  2005        PMID: 16210408     DOI: 10.1634/stemcells.2005-0014

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  51 in total

1.  Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient?

Authors:  Aileen J Anderson; Daniel L Haus; Mitra J Hooshmand; Harvey Perez; Christopher J Sontag; Brian J Cummings
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

Review 2.  Current methods and challenges in the comprehensive characterization of human pluripotent stem cells.

Authors:  Joanna S T Asprer; Uma Lakshmipathy
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

Review 3.  Opportunities and challenges: stem cell-based therapy for the treatment of ischemic stroke.

Authors:  Yao-Hui Tang; Yuan-Yuan Ma; Zhi-Jun Zhang; Yong-Ting Wang; Guo-Yuan Yang
Journal:  CNS Neurosci Ther       Date:  2015-02-10       Impact factor: 5.243

4.  Stem cells for reprogramming: could hUMSCs be a better choice?

Authors:  Paulina Duya; Yuhong Bian; Xiaoqian Chu; Yanjun Zhang
Journal:  Cytotechnology       Date:  2012-09-12       Impact factor: 2.058

5.  WNT signaling in stem cell differentiation and tumor formation.

Authors:  Hong Ouyang; Yehong Zhuo; Kang Zhang
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

6.  In vivo bone formation by progeny of human embryonic stem cells.

Authors:  Sergei A Kuznetsov; Natasha Cherman; Pamela Gehron Robey
Journal:  Stem Cells Dev       Date:  2010-09-14       Impact factor: 3.272

7.  Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum.

Authors:  Igor Nasonkin; Vasiliki Mahairaki; Leyan Xu; Glen Hatfield; Brian J Cummings; Charles Eberhart; David K Ryugo; Dragan Maric; Eli Bar; Vassilis E Koliatsos
Journal:  Stem Cells       Date:  2009-10       Impact factor: 6.277

8.  Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection.

Authors:  Ivan Gutierrez-Aranda; Veronica Ramos-Mejia; Clara Bueno; Martin Munoz-Lopez; Pedro J Real; Angela Mácia; Laura Sanchez; Gertrudis Ligero; Jose L Garcia-Parez; Pablo Menendez
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

Review 9.  Engineering Stem Cell Organoids.

Authors:  Xiaolei Yin; Benjamin E Mead; Helia Safaee; Robert Langer; Jeffrey M Karp; Oren Levy
Journal:  Cell Stem Cell       Date:  2016-01-07       Impact factor: 24.633

Review 10.  Lessons from human teratomas to guide development of safe stem cell therapies.

Authors:  Justine J Cunningham; Thomas M Ulbright; Martin F Pera; Leendert H J Looijenga
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.